Literature DB >> 11045999

Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance.

L Graca1, K Honey, E Adams, S P Cobbold, H Waldmann.   

Abstract

Nondepleting anti-CD154 (CD40 ligand) mAbs have proven effective in inducing transplantation tolerance in rodents and primates. In the induction phase, anti-CD154 Ab therapy is known to enhance apoptosis of Ag reactive T cells. However, this may not be the sole explanation for tolerance, as we show in this study that tolerance is maintained through a dominant regulatory mechanism which, like tolerance induced with CD4 Abs, manifests as infectious tolerance. Therefore, tolerance induced with anti-CD154 Abs involves not only the deletion of potentially aggressive T cells, but also a contagious spread of tolerance to new cohorts of graft-reactive T cells as they arise.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045999     DOI: 10.4049/jimmunol.165.9.4783

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.

Authors:  Laurence M Howard; Serge Ostrovidov; Cassandra E Smith; Mauro C Dal Canto; Stephen D Miller
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 2.  TGF-beta, T-cell tolerance and anti-CD3 therapy.

Authors:  Ramireddy Bommireddy; Thomas Doetschman
Journal:  Trends Mol Med       Date:  2004-01       Impact factor: 11.951

Review 3.  Transplantation: focus on kidney, liver and islet cells.

Authors:  Edward N Chang; Charles H Scudamore; Stephen W Chung
Journal:  Can J Surg       Date:  2004-04       Impact factor: 2.089

Review 4.  Tregs and transplantation tolerance.

Authors:  Patrick T Walsh; Devon K Taylor; Laurence A Turka
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 5.  Homeostatic T cell proliferation as a barrier to T cell tolerance.

Authors:  Somia P Hickman; Laurence A Turka
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

6.  Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance.

Authors:  Thomas B Thornley; Nancy E Phillips; Britte C Beaudette-Zlatanova; Thomas G Markees; Kapil Bahl; Michael A Brehm; Leonard D Shultz; Evelyn A Kurt-Jones; John P Mordes; Raymond M Welsh; Aldo A Rossini; Dale L Greiner
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

7.  Langerhans cells are not required for efficient skin graft rejection.

Authors:  Jagdeep S Obhrai; Martin Oberbarnscheidt; Na Zhang; Daniel L Mueller; Warren D Shlomchik; Fadi G Lakkis; Mark J Shlomchik; Daniel H Kaplan
Journal:  J Invest Dermatol       Date:  2008-03-13       Impact factor: 8.551

Review 8.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

Review 9.  Retinoic acid in the immune system.

Authors:  Karina Pino-Lagos; Micah J Benson; Randolph J Noelle
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 10.  The platelet as an immune cell-CD40 ligand and transfusion immunomodulation.

Authors:  Neil Blumberg; Sherry L Spinelli; Charles W Francis; Mark B Taubman; Richard P Phipps
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.